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The nations of the European Union (EU) 
spent €80 billion ($100 billion) last year on 
public nonmilitary research and develop-
ment, yet European science still seems 
to have a quality gap compared with the 
US. For example, the EU produces 33% of 
research papers published annually world-
wide but garners only 34% of citations, 
compared with the US, which publishes 
29% of papers but earns 41% of citations 
(http://www.nsf.gov/statistics/seind08/). 
Policymakers believe that one reason for 
this quality shortfall is the fragmentation 
of research spending in Europe. Accord-
ing to the European Commission based 
in Brussels, 85% of public research funds 
in Europe are distributed through sepa-
rate national programs run by the EU’s 27 
member states. Many think that the way to 
get more bang for their euro is to tie these 
national activities more closely together.
Multiple attempts to unite different 
European research programs have 
failed, however. The €7 billion that the 
European Commission allocates for 
research annually through its Frame-
work Programme is supposed to nur-
ture cross-border collaborations but 
does so one project at a time. And 
other efforts—including the long-
established European Cooperation 
in Science and Technology (COST) 
scheme and plans in the Framework 
6 Programme (which ran from 2002 
to 2006) for “integrated projects” and 
“networks of excellence”—tried and 
failed to link the national research pro-
grams together. All of these efforts have 
foundered on a mixture of bureaucracy, 
nationalism, inertia, and the reluctance 
of top researchers, who are able to get 
funding in their own countries, to get 
involved. “It is very difficult for member 
states to come together on a common 
basis,” concedes Enda Connolly, chief 
executive of Ireland’s Health Research 
Board, which distributes €40 million 
annually for biomedical research in Ire-
land. “They are all locked into their own 
programs.”
In the last 2 years, however, a new 
fix has been proposed for the problem: 
“joint programming” between national 
research agencies. The idea is to get 
interested nations to band together 
and agree on a detailed strategy for a 
given research field and then pick-and-
choose which elements of that strategy 
to collaborate on. “Joint programming 
is critical to the future, but it is still in 
gestation,” says Frank Gannon, former 
director of the European Molecular Biol-
ogy Organization and current member 
of the European Research Area Board, 
which advises the European Commis-
sion. “From my point of view, it is cur-
rently the most crucial, single thing that 
we have to put right.”
Last December, the Council of Ministers 
representing the EU member states con-
firmed that the first joint programming pilot 
project would focus on neurodegenerative 
disease research, which is particularly 
weak and fragmented in Europe (Figure 
1). The European Commission’s research 
directorate estimates that US spending in 
this area ($856 million, or €527 million, in 
2007) is almost ten times that of Europe 
($93 million, or €57 million).
Alzheimer’s disease researcher Bart 
De Strooper of KU Leuven in Belgium 
agrees that neurodegenerative dis-
ease research is lagging in Europe. “My 
impression is that in the United States, 
much more of a vision has been devel-
oped with regard to problems of aging, 
and Alzheimer’s in particular,” he says, 
pointing to collaborations such as the 
Alzheimer’s Disease Neuroimaging Ini-
tiative (http://www.loni.ucla.edu/ADNI/), 
which is supported by several institutes 
of the National Institutes of Health (NIH) 
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Figure 1. Europe’s Research Landscape
Brain disease research in Europe, including the study of neurodegenerative diseases such as Alzheimer’s 
and Parkinson’s, is weakly coordinated across Europe and receives less investment compared with the 
US. (x axis, degree of coordination; y axis, spending in Europe relative to the US). Source: European 
Commission, 2008 (ec.europa.eu/research/press/2008/pdf/com_2008_468_en.pdf).
348 Cell 142, August 6, 2010 ©2010 Elsevier Inc.
and the private sector. “We in Europe 
look to the US and are happy if some of 
us are incorporated in their initiatives,” he 
says. “We should be much more active 
on the international scene.”
The idea of a combined approach 
to boost neurodegenerative disease 
research was first proposed in 2008, 
when France held the rotating presi-
dency of the EU and President Nicolas 
Sarkozy sought to push aging issues 
higher up Europe’s research agenda. 
In July of that year, the European Com-
mission issued a paper advocating joint 
programming as a generic approach to 
improving coordination among national 
research bodies. Meanwhile, medical 
research agencies in France, Germany, 
and the UK were already seeking ways 
to strengthen their respective involve-
ment in an area of biology where the US 
has a pronounced lead (http://www.mrc.
ac.uk/Utilities/Documentrecord/index.
htm?d=MRC004898).
Philippe Amouyel, an epidemiologist 
at the University of Lille in France, led 
a working group established in 2008 to 
look into the idea of joint programming 
in the discipline and is now chair of the 
board of the EU Joint Programme for 
Neurodegenerative Disease. (Connolly 
also sits on the initiative’s five-person 
management board.) Initially supported 
by INSERM, the French biomedical 
research agency, the working group now 
has a small €2 million European Com-
mission grant to cover its administration 
costs.
The Joint Programme has appointed 
a fifteen-member scientific advisory 
board, which met in Stockholm in April 
and will now draw up a 5 year strate-
gic plan for neurodegenerative disease 
research in Europe. The board is made 
up of five social scientists, five clini-
cians, and five biologists: Jesus Avila 
of the University of Madrid, Bart De 
Strooper, John Hardy of University Col-
lege, London, Leszek Kaczmarek of the 
Polish Academy of Sciences and the 
chairman, Thomas Gasser of the Uni-
versity of Tubingen. There is no budget 
yet to implement the plan, but officials 
involved in the discussions say that it is 
likely to involve an investment of about 
€200 million over 5 years, mainly from 
national funding bodies. “For the very 
first time,” says Amouyel, “we’ll have 
a common view in Europe of what we 
need to do in neurodegenerative dis-
ease research.”
Most of the research supported will 
be in basic neurobiology, including 
sequencing the complete genomes of 
patients to find risk genes, the devel-
opment and standardization of disease 
biomarkers, and developing better ani-
mal models of these diseases. “The big 
problem is that we don’t have a pipeline 
for new therapies, so we need to better 
understand the fundamental pathophys-
iology of these diseases,” says Rob 
Buckle, program manager for neurosci-
ences and mental health at the UK Medi-
cal Research Council (MRC). “This is an 
opportunity to do things in a different 
way in Europe.” Buckle says he hopes 
that the Joint Programme will do work 
that could be relevant to the treatment of 
several neurological diseases, including 
Parkinson’s and motor neuron disease, 
as well as Alzheimer’s. “Mechanistically, 
there’s a lot of overlap between these 
disorders,” he says.
Gasser, a neurologist who studies 
Parkinson’s disease, says the scien-
tific advisory board will confer broadly 
before publishing its research plan in 
summer 2011. Three meetings early next 
year, involving interested biologists, cli-
nicians, and social scientists, respec-
tively, will help the process along. Gas-
ser adds that there is a “huge political 
will” to make the Joint Programme work 
but notes that its directed approach “will 
never displace bottom-up, undirected 
basic research that can give us com-
pletely new insights.”
There are already some examples 
of the kinds of collaboration that might 
proceed under the Joint Programme. On 
June 29th, for example, the UK MRC, 
the German Centre for Neurodegenera-
tive Diseases (DZNE), and the Canadian 
Institutes of Health Research (CIHR) 
announced a £3 million ($4.6 million) col-
laboration on methods, technologies, 
and data sharing in neurodegenerative 
disease research. (Canada’s involvement 
reflects the MRC’s desire to cooperate 
with partners outside Europe who have 
relevant expertise.) And Amouyel says 
that some test projects may go ahead 
under the Joint Programme before the 
strategic plan’s completion, in areas such 
as genomics, the standardization of bio-
markers, developing new therapeutics, 
and infrastructure for large clinical trials. 
“They could get going by the end of the 
year,” he says, adding that the initiative 
is moving quickly. “To get something 
from concept to practical action in three 
years is really new in European research 
policy.”
De Strooper adds that as a researcher 
in Belgium, he sees advantages in col-
laborating with larger countries—France, 
Germany, and the UK—that are starting 
initiatives in neurodegenerative disease 
research. He says that he hopes the 
Joint Programme will help researchers to 
do animal modeling and drug screening, 
obtain microRNA profiles of patients, 
and do deep sequencing and annota-
tion of expression profiles for Alzheim-
er’s and other diseases. Alzheimer’s 
researcher and geneticist John Hardy 
says he hopes that the program can 
help researchers to find better biomark-
ers for neurodegenerative diseases and 
to use rapid, full-genome sequencing of 
patients to find the risk genes for them. 
But he admits that it is too early to know 
how it will unfold. “You get involved in the 
process, but you never know if there’s 
going to be a good outcome,” he says. 
“There is a genuine need for it. But you 
do worry that the optimism behind the 
programme will end up clashing with the 
hard reality of budget cuts.”
Although the joint programming pilot 
has been broadly welcomed, many 
experienced researchers and research 
administrators have questioned whether 
the joint programming approach has 
enough backing or momentum to have 
much impact on fragmented European 
research. Critics charge that the overall 
approach is ill-defined, inadequately pro-
moted, and—most of all—underfinanced. 
Physicist and European Research Advi-
sory Board member Jerzy Langer of the 
Polish Academy of Sciences says he 
fears that it won’t get much further than 
a long line of prior Commission efforts to 
get national research agencies to work 
more closely together. “I’m not saying 
it is wrong,” he says. “But any initiative 
that starts from the bureaucracy tends to 
go nowhere.” Langer contends that joint 
programming still has little constituency 
among researchers. “The key question,” 
he says, “is when, and in what capacity, 
real researchers get involved.”
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“There is serious added value to be 
achieved if we can use joint program-
ming to get national funding used more 
effectively,” says Ian Halliday, president 
of the European Science Foundation in 
Strasbourg. “But politically and organi-
zationally, this is not going to be easy.” 
And observers of the joint programming 
pilot say that the MRC and INSERM are 
already frustrated by the need to accom-
modate participation by the 24 EU nations 
who have signed up for the pilot—many 
of whom cannot contribute much in the 
way of cutting-edge neurobiology. Some 
suggest that participants will have to 
learn to do what physicists have done at 
CERN, the successful European particle 
physics center in Switzerland, and find 
ways of accommodating partners who 
are less scientifically advanced.
Buckle denies that this is a problem 
for the MRC, arguing that the Joint Pro-
gramme for Neurodegenerative Disease 
will be an “umbrella” for the sharing of 
information and will allow “different con-
stellations” of nations to work together 
on different areas of interest. “Everyone 
involved will be signed up to the same 
top-level objectives,” he says, “but 
everyone will have different interpreta-
tions of how to best achieve them.”
Backers of joint programming say it 
can work because it is the EU member 
states, through the Council of Ministers, 
who have endorsed the approach and 
have pledged to see it through. “For the 
first time, member states are coming 
together at the ministerial level to iden-
tify jointly areas where public research 
can contribute to tackling Europe’s 
major societal problems,” said Maire 
Geoghegan-Quinn, the newly appointed 
European Commissioner for research, 
in a statement. “It is precisely because 
it is underpinned by a high-level, strate-
gic and structured process—and most 
importantly of all, by real political will—
that joint programming is a very big step 
forward.”
The Commission’s approach to the 
idea is finely nuanced, however, because 
if joint programming is seen as a Com-
mission project, member states will 
view it as a means of getting Commis-
sion money. So Commission officials are 
orchestrating it from behind the scenes, 
hoping that national governments will 
take the actions needed to provide 
money and drive it forward. But there are 
hints that large-scale Commission fund-
ing to support joint programming could 
become available under the next phase 
of the Framework Programme, FP8, 
which starts in 2014.
Governments are certainly watching 
the pilot with interest. In April, the Com-
mission recommended three further 
pilots—in food security, healthy diets, 
and cultural heritage conservation. In 
tough economic times, at least in theory, 
joint programming could help to reduce 
duplication enabling research funds to 
be spent more efficiently. “In a way, a 
shrinking budget is an opportunity,” says 
Amouyel, “because you have to allocate 
resources more efficiently.” And in fields 
such as neurodegenerative disease, 
where even the largest national research 
agencies cannot cover every aspect, the 
joint programming approach may help.
Yet the odds remain stacked against 
it making much difference: EU member 
states control five-sixths of Europe’s 
research budget, and they want to spend 
it on their own scientists. A 2009 study 
by Eurohorcs, the federation of national 
research councils, found that 14 out of 
32 of the national agencies surveyed had 
legal prohibitions on supporting work 
outside their borders (http://www.era.
gv.at/attach/EUROHORCs.pdf). At the 
larger agencies, around 5% of the budget 
is usually devoted to collaborations with 
European partners (some small agen-
cies, such as the Foundation for Polish 
Science and the Greek National Hellenic 
Research Foundation, spend proportion-
ally more). The perceived political draw-
backs of spending dwindling research 
funds “abroad” remain daunting, however. 
And there is a strong imperative within 
national research agencies to hold on to 
control of what they have. “There’s always 
going to be people at national agencies 
who fear that they could lose out” from 
joint programming, agrees Connolly. “But 
there’s very strong commitment at the 
political level, and in the European Com-
mission, to making this happen. Member 
states are coming to see that they can’t 
do everything on their own.”
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